Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Translate Bio, Inc.    TBIO

TRANSLATE BIO, INC.

(TBIO)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/05/2020 08/06/2020 08/07/2020 08/10/2020 08/11/2020 Date
15.17(c) 15.22(c) 14.73(c) 15.17(c) 14.23(c) Last
939 681 1 160 836 1 334 411 1 258 646 1 323 296 Volume
-1.43% +0.33% -3.22% +2.99% -6.20% Change
More quotes
Financials (USD)
Sales 2020 42,0 M - -
Net income 2020 -103 M - -
Net cash position 2020 665 M - -
P/E ratio 2020 -9,36x
Yield 2020 -
Sales 2021 43,5 M - -
Net income 2021 -113 M - -
Net cash position 2021 657 M - -
P/E ratio 2021 -10,4x
Yield 2021 -
Capitalization 1 056 M 1 056 M -
EV / Sales 2020 9,32x
EV / Sales 2021 9,18x
Nbr of Employees 93
Free-Float 87,3%
More Financials
Company
Translate Bio, Inc. is a messenger RNA, or mRNA, therapeutics company. The Company is developing medicines to treat diseases caused by protein or gene dysfunction. The Company is using its proprietary mRNA therapeutic platform, or MRT platform, and it create mRNA that encodes functional proteins. The mRNA is delivered to the target cell where the cell’s own machinery recognizes it and translates it, restoring or... 
More about the company
Latest news on TRANSLATE BIO, INC.
08/06Translate Bio Announces Second Quarter 2020 Financial Results and Reviews Rec..
GL
08/06TRANSLATE BIO : Management's Discussion and Analysis of Financial Condition and ..
AQ
07/31INVESTIGATION ALERT : The Schall Law Firm Announces it is Investigating Claims A..
BU
07/29Sanofi lifts earnings view as Regeneron stake sale boosts second quarter
RE
07/29Sanofi lifts earnings view as Regeneron stake sale boosts Q2
RE
07/20Translate Bio Expands Collaboration with Sanofi For Infectious Disease Vaccin..
DJ
07/20TRANSLATE BIO, INC. : Other Events (form 8-K)
AQ
07/20Translate Bio Announces Closing of Expanded Collaboration and Licensing Agree..
GL
07/02Tesla to make molecule printers for COVID-19 vaccine developer CureVac
RE
07/01BioNTech and Pfizer's COVID-19 vaccine shows potential in human trial
RE
06/29Temasek-led investor group in $250 million vaccine bet on Germany's BioNTech
RE
06/26TRANSLATE BIO, INC. : Entry into a Material Definitive Agreement, Other Events, ..
AQ
06/26French drugmaker Sanofi to cut up to 1,680 jobs in Europe
RE
06/26French drugmaker Sanofi to cut up to 1,680 jobs in Europe
RE
06/25TRANSLATE BIO : Announces Pricing of Public Offering of Common Stock
AQ
More news
News in other languages on TRANSLATE BIO, INC.
08/06Translate Bio Announces Second Quarter 2020 Financial Results and Reviews Rec..
08/06TRANSLATE BIO : Management's Discussion and Analysis of Financial Condition and ..
07/31INVESTIGATION ALERT : The Schall Law Firm Announces it is Investigating Claims A..
07/29Sanofi lifts earnings view as Regeneron stake sale boosts second quarter
07/29Sanofi relève sa prévision de bénéfice pour 2020
More news
Chart TRANSLATE BIO, INC.
Duration : Period :
Translate Bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TRANSLATE BIO, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 31,71 $
Last Close Price 14,23 $
Spread / Highest target 181%
Spread / Average Target 123%
Spread / Lowest Target 75,7%
EPS Revisions
Managers
NameTitle
Ronald C. Renaud President, Chief Executive Officer & Director
Daniel S. Lynch Chairman
Paul Burgess Secretary, Chief Operating & Legal Officer
John R. Schroer CFO, Treasurer & Principal Accounting Officer
Ann Barbier Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
TRANSLATE BIO, INC.74.82%1 056
GILEAD SCIENCES, INC.4.80%85 893
VERTEX PHARMACEUTICALS19.60%69 995
REGENERON PHARMACEUTICALS59.49%64 005
WUXI APPTEC CO., LTD.72.11%38 467
GENMAB A/S53.90%23 539